Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22000Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tsouli, S. G. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Athyros, V. G. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:19:58Z | - |
| dc.date.available | 2015-11-24T19:19:58Z | - |
| dc.identifier.issn | 0026-0495 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22000 | - |
| dc.rights | Default Licence | - |
| dc.subject | Animals | en |
| dc.subject | Humans | en |
| dc.subject | Hyperuricemia/*blood/physiopathology | en |
| dc.subject | Metabolic Syndrome X/*blood/physiopathology | en |
| dc.subject | Uric Acid/*blood | en |
| dc.title | Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.metabol.2006.05.013 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16979398 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0026049506001806/1-s2.0-S0026049506001806-main.pdf?_tid=e7dcbd8da3c22538fd1da5a163f28904&acdnat=1333539038_2154ea81a601c7456586b60763929f3d | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2006 | - |
| heal.abstract | Elevated serum uric acid (SUA) levels are commonly seen in patients with the metabolic syndrome (MetS). Several mechanisms, both direct and indirect, connect the increased SUA levels with the established diagnostic criteria of MetS. It is possible that the increased cardiovascular disease risk associated with the MetS is partially attributed to elevated circulating SUA concentration. Several drugs used in the treatment of MetS may alter SUA levels. Thus, lifestyle measures together with the judicious selection of drugs for the treatment of hypertension, dyslipidemia, and insulin resistance associated with MetS may result in a reduction of SUA levels and possibly cardiovascular disease risk. This review summarizes the pathophysiologic association between SUA and MetS and focuses on the prevention of hyperuricemia and its cardiovascular consequences. | en |
| heal.journalName | Metabolism | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Tsouli-2006-Elevated serum uric.pdf | 171.51 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
